Takeda partners with Biological E to boost dengue vaccine production in India
Japan's pharma company Takeda partners with Indian vaccine and biologic company Biological E to boost the manufacture of Takeda's dengue vaccine, TAK-003.
Source: PTI representative
The partnership is likely to enhance vaccine manufacturing capabilities, with Biological E scaling up its production capacity to potentially reach 50 million doses annually.
Source: Shutterstock/Representative
This will accelerate Takeda's goal of producing 100 million doses within this decade.
Source: Unsplash
The announcement was made at BioAsia 2024, a regional life science and healthcare forum organised by the Government of Telangana.
Source: Shutterstock
Dengue, the fastest-spreading mosquito-borne viral disease, puts about half of the world's population at risk.
Source: Instagram
This partnership is expected to boost access to the vaccine in dengue-endemic countries, reducing the health impact significantly.
Source: Unsplash
TAK-003 has shown significant protection against dengue in long-term studies and has been approved in over 30 countries.
Source: Unsplash
The partnership aims to further expand this reach, combating unmet public health needs worldwide.
Source: ANI
This announcement aligns with the World Health Organization’s (WHO) goal to achieve zero case-fatality rate due to dengue by the year 2030.